DARE - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended September 30, 2020, and to provide a general business update. This call is being recorded. My name is Chris, and I will be your operator today. With us today are Sabrina Martucci Johnson, Daré's President and Chief Executive Officer; John Fair, Daré's Chief Strategy Officer; and Lisa Walters-Hoffert, Daré's Chief Financial Officer. Miss. proceed. please Johnson,

Sabrina Martucci Johnson

welcome call and financial and results Thank Daré to Bioscience. update for business you, our

We forward in on of plans some developments are for results milestones XXXX important quarter looking and perspective achievements to and discussion XXXX. providing to regarding the date for XXXX some anticipated third highlighting remainder our our reflecting

are made Safe Before I'd like federal could statements discussion unknown undue provisions and statements not forward-looking forward-looking events differ considered include materially meaning Private we and be known risks from Reform statements. due to of today's Securities to and the during or historical begin, Act Any within laws, therefore place statements call these not facts uncertainties you those securities pursuant of should the are should by of reliance or statements. which Actual will that Harbor statements so remind forward-looking results you to this the anticipated on Litigation of that made implied XXXX.

Daré after November law. required XXXX. includes information or this was new that filed XX, except today. are forward-looking on our statements Form ended this I'd no is December the of by Annual for the also our including statements XX-K their qualified call, as out XXXX update XX, XX, was on that September time-sensitive entirety on which in any Form information call filings, SEC which filed XXXX, the today, reflect only Report like content XXXX of obligation year company's XX, for quarterly cautionary to ended developments by the quarter to point current report to as March takes and statements in XX-Q Forward-looking the

life Daré Now wellbeing health leader and on is of the improving innovation and as women's women. we're squarely focused you in know, a

programs in women have strategy category to and potential to availability candidates for by and believe first we Our be opportunity of the line with vaginal meaningful and new products have value creation clinical health, that accelerate selecting commercial in and contraception stage product first prescription is advancing four menopause.

to affect estimated are of our million therapies the the Phase care [Indiscernible] end readout current is of DARE-BVX considered and improvement existing clinical approach the year. in the is option approximately X DARE-BVX serious this meaningful to be for new XX DARE-BVX potential data that vaginosis, line the alone. U.S. rate women particularly program first we a for looking As to potential has deliver over approved we our XXXX, products. top our bacterial forward line the condition a in FDA to Many are

end excited last the We month X involvement this last before that subjects announce visit. have We top Phase completed to line completed in was data are study also the their expect all and to therefore year. report of

will additional market as as upcoming we and call steps towards eventual the and next X support provide the context on well submission strategy today’s to DARE-BVX Phase partnering During read commercialization. introduction out regulatory

vaginal contraceptive activities we We Ovaprene branded which FSAD, to monthly in disorders address agreement female world a is to including leader And investigational of the to arousal Cream novel XXXX, Xb under female support potential our plan dysfunction the sexual developed erectile to being or men. development in dysfunction provide commence the Sildenafil a our to Phase updates contraceptive most activities hormone candidate in first-in-category only discuss analogous a on will for program, knowledge also market. the license sexual and we’ll program Bayer to disorder with free contraceptive on-going the

reflecting do partnering read Before several XXXX. want years planned next of and as commercial candidates. each by moment milestones those us. XXXX top our accomplishment we product a the three on year we value to provide across first But of announcing including on data as updates in Daré, line date for a in the opportunities. year the looking our believe near of drivers term occurring We incorporate outs anticipated partnership our for that for to well spend January we our number been forward started achieved strategy, quite of agreement. has important strategy our We a firsts serve all year as validation first regulatory

Bayer’s impact the capital represents commercial any double transaction provide contraceptive the We dollar on of franchise, under only payable in also license business exclusively of are up Ovaprene, Daré Daré’s million of in general terms conditions Bayer operations satisfaction clinical anticipated United the achieve knowledge, in the the States certain commercial the on commercial they To and the for disclose payment of potential can the investigational tiered but plus Shortly objectives. transaction not Global which of a to include announced digits. in the after the we're year, agreement, and companies, COVID-XX entered life had model pivotal on as Specifically, milestones. on opportunity, pandemic, payments contend regulatory contraceptive sole with stage in the following all start largest discretion us into completion agreement, aggregate milestone marketers we also trial to value. which million to business our to license our Ovaprene partnerships our the contraceptive and agreement development billion $XXX the we first-in-category believe sales of science commercialize with our of product Mirena a validates net and the milestone by $XX royalties the with such eligible receive strategic a Bayer Under Bayer transaction Ovaprene. the of to the

able stage previously we enabling align with environment, were line to advance limitations However, top the of fortunate our current that recalibrate better the and to to to programs our target we continue data the projected. were us readouts towards activities clinical

confirm commenced that free previous based study a readout guidance. top to June, the excited we at treatment our trial trial major X DARE-BVX that for bacterial As milestone of data which from And to pivotal this vaginosis Phase our results own. of its have our expect for the in Daré first we're year, Daré, on we line is

the DARE-BVX positive also outcome, of for Phase during XXXX. late drug submission, We application half to advance and action first a into were new we or Assuming XXXX. positions NDA potentially study novel in a as clinic XXXX, the also in X the able believe regulatory another program

clinical vasomotor enrolling Phase Our receive and than our expect X form study, conducting originally for potentially DARE-HRTX have in our subsidiary with share a U.S. started in to of Australia, address program, the DARE-HRTX technology excited and study line cash successful, in If of approaching this innovative July, associated or We XXXX. in XX payments way this to In half strategy the Phase have the but the offers are the and delivers symptoms ring patients clinical potential symptoms top to which one menopause, more candidate alone, vaginal we be into only Australia I vasomotor estimated ring which first identical thus at results a also utilizes research our We're Australia. our cost are also vaginal in study mentioned, for that more through for developed incentives technology menopause. X as same treatment the in successfully our for not product to women we new tax the data, time menopause. million leverages MIT, of DARE-FRTX, utilizes our utilizing efficient the and to could bio a R&D as provide with first in and eligibility progesterone. and subsidiary you been convenient that important DARE-HRTX

luteal DARE-FRTX, phase as of we're of recall, may treatment regimen. for a developing in-vitro as you support option part prevention the As and more birth an broader fertilization convenient preterm

Phase Another the of Eunice of for when announced we Child DARE-FRTX. Kennedy exciting NIH funding grant and Development, X clinical of is NIH support study from to division was in announced development we of Shriver for National phases. Daré a a awarded Health Human received notice the a award in August Institute that

reversible So in up XXXX, in eligible of total also award XXXX, support under funding to segment grant human and and granted in year DARE-FRTX $XX.X XXXX, receive I a in And Phase funding our XXX,XXX. of a receipt the date the approximately for Gates program, an Melinda up line outlined approximately a year the controlled reversible to the grant from contraceptive approximately for for Foundation. of DARE-LARCX Gates and NICHD project Daré. milestones acting study. by controlled we technology to X.X additional been of our award has been solution, XXXX with as today. current grant be that Melinda a grant user it's breakthrough of important million to in the next in total of firsts, the X.X application we X non-diluted sum contraceptives And Bill our the long for if million long Bill were in year strategy million may Thus Foundation user funding DARE-LARCX then announced acting the and potential the to first clinical supported is is funding from

on that With As some continuing highlighted expect that talking about, to like we capital XXXX. have partnerships, accomplishments study look perspective in we the initiations, XXXX. we non-dilutive provide the forward what in been in I'd and to the that momentum said,

First, with as DARE-BVX associated I the milestones there important of are mentioned, number program. a

a formulation rate of is for meaningful to a products designed has in over the current approved So Phosphate bacterial which administration clinical hydrogel Clindamycin cure done vaginal thermosetting a potential X% and one in DARE-BVX deliver the as improvement novel the vaginosis. FDA

test cure standard-of-care at As vaginosis study after DARE-BVX initiated comparison, at pivotal rates that a in X marketed a for the demonstrate cure Phase on that X of occurred rate the XXs mid a of currently with cured In a we demonstrated ranging to could If products invaluable treatment DARE-BVX. clinical day DARE-BVX clinical of option administration XXs, delivers treatment the women the an high-XXs vaginosis. compared become to bacterial to approved we mid-XXs to of cure range proof-of-concept new data of FDA percentage for reported, visits XX single rate clinical cure basis. frontline that superior subjects in have days the high studies previously diagnosed bacterial believe XX% current that efficacy the from investigator the from study of

FDA we in the Importantly, bacterial We the FDA successful. DARE-BV plan DARE-BVX that request designations pre-NDA of the can free XXXX early NDA submit infectious received half meeting with XXXX both fast track vaginosis. such qualified the that treatment study disease and assuming that for of first product a for is to from

NDA have PDUFA and the product priority early we infectious granted, if that XXXX would launch commercial for U.S. disease that qualified and and for date Given track assuming approval status, the should be XXXX allow eligible in fast which review,

for the care, additional going provide heels the planned eventual us want commercialization. to vaginosis process current pleased John of how the optionality to our the this of are compared our supporting treatment approaching of capture the post partnering the bacterial investors Given optionality to and to Phase that complete contemplated the to on with structures prevalence this prospects on putting ultimate us maximum program standard and deal and provide. the the this insights and I are Phase strategic moment take this DARE-BVX exercise for always this X benefits partner We've But we structure. X is value potential partnering shareholders. have thank the to study position being data for to of we to in study on

Phase cream, Sildenafil Xb top important Sildenafil of anticipate by Ovaprene In also data of We Xb quarter for the programs XXXX, the first and study end for of Phase in our potential line readout XXXX. that us anticipate we the study positioning for Cream commencing XXXX. milestones

Our no SFAD. has dysfunction be categories disorder U.S. sexual most is Sildenafil being female potential to Cream market drug significant our to product so, if address Sildenafil is first only And product to in for being under Research for program condition. the oral approved the condition are the in in not men, analogous mentioned sexual knowledge as be that the of I female sexual XX% ingredient or suggests are in to to distressed low FDA the as arousal currently is marketed in active that Market the the and erectile Sildenafil U.S. for improve XX% administration symptoms treatment of a XX dysfunction arousal, brand solution to ages tablets seeking the SFAD potential more arousal in as developed market selected name, erectile “Viagra” And XX erectile and women their Cream, disorder. potential men. the we've which dysfunction the first estimated to experienced of

to X% that of estimated put age only of In Let's XX, about context only XX. prevalence perspective. erectile the erectile men in of age the XX% dysfunction, increasing be at dysfunction to complete is at

X in Ovaprene. The other candidate Phase portfolio is our

pivotal that study should XXXX. XXXX, line by year us We end by for expect report which study data Ovaprene top end to position to our commence year pivotal

ever monthly the in I As to it be Ovaprene free approved, hormone Worldwide prevention offer monthly the is contraceptive, could a product for currently free more first $XXX non-hormonal sales and the convenient pregnancy. the compelling mentioned, monthly potential solutions. of and seeking increasing XXXX. women with new were number an first contraceptive option vaginal hormone for contraceptive hormonal million investigational and If Ovaprene development monthly the contraceptive reliable, for [Ph] of product, of

with strategy, to next second will next the FDA’s discussions application for Ovaprene months the continue process using those clearance review with IDE last by an that pivotal to prepare non-clinical continue regulatory and and FDA to program. investigational FDA We've the of the that intend exemption XXXX. we study several that months to submission in year Ovaprene the activities align plan leverage and XXXX. initiate pre-submission the end device of to file the or several the plan Pending to to been to half months, utilize IDE, and Over continue we on advance and manufacturing development the several

data to approval the the the countries studies I well this As well. readout year-end to marketing mentioned as U.S. as for in top data we Ovaprene support support one successful, line U.S. If XXXX. as that by outside expect

and our XXXX Phase and programs of that of addition treatment DARE-FRTX we initiate DARE-BVX activities DARE-HRTX, In for of DARE-VVAX line for stage Ovaprene both program. the mentioned, study X top the NIH the our to I and readout Phase as our late candidates vasomotor for Sildenafil mentioned, has menopause which to symptoms X anticipate from also already related program, funding in the Cream the

hormone receptor and free DARE-VVAX our hormone Atrophy for in positive Vulvar Vaginal cancer may breast You recall is that a population. treatment

business its and health results XXXX indications women's that our potential. diversity our model demonstrate development core variety the a plans is Our XXXX our to of our driving of feature the and Namely, our and programs value of stages programs enable simultaneously, efficient portfolio numerous program can the capital a challenging our resources to demonstrated across and ways have both investment direct in as against manner, even that in advance and milestones the environment. time in us this we of a

and to spread to do business definitely slow pandemic the to the potential of business restrictions rapidly anticipated on put evolving track we costs in now and circumstances. deliver Currently a to candidates, course, and will update. the call top remain just closely milestones over increase study partnership to top timelines Of line and product however we've with timelines John in regulatory discussed. we that recognize our place and provide for turn COVID-XX the clinical lines I'll have target results the monitor we our disrupt development continue to corporate on the

John Fair

for to and well partnerships strong, our Strategic comes Sabrina. unlock well-established companies, both you, pharmaceutical as core plan our and has and it in Thank continues value emerging commercialization companies, we objectives of U.S. for from how portfolio portfolio. model, level our be and are interest shareholders, large been to The particularly to mid-sized to global. both when as achieve

stewards population being of can have partnerships, are advancing the maximize impact patient on and will that discussions actively and lives to value. provide same women, we By these broadest execution shareholder at delivering therapeutic we good We while commercial believe the respective partnership categories. time to the positive the allow believe in we of products us downstream a access

create fit expect will partnership commercial opportunity partnerships, indications. and looking shareholders, companies There lot a from you familiar commercial best amortize category, portfolios of their entities us a emerging opportunities across transition portfolio. care the are dynamics our commercial partnerships, will and of a to provider especially for efficiencies value their of call flexibility we from you field category, -- Salesforce the as timing a point in costs, we portfolio of women's for the development and which allow health to health multiple finding terms targeted meaning established in enhance a number and create also a commercial For with that those to appreciate and for structures, give of

acting monthly milestones hands As robust with us they which and also flexibility vaginal form Daré commercial our where royalties, commercialization, such with dollar investigational commercial of partner, Bayer look launch partnership gives we the an at structures bearing for while putting for candidates, economic look co-promotion, to of risk billion other example, the ring for their sharing, we agreement active beyond commercial contraceptive hormone and But and the provides include same an as maximum without segment. expand Mirena franchise Bayer time role opportunities structure commercialization have sharing of in long elements the our the cost a as believe the to strategic the beyond in Ovaprene market our burden takes may expenses. free more and infrastructure of opportunity by product and the Ovaprene associated the

and potential have Given these the portfolio candidates, to the flexibility our capability first-in-line of underlying licensing this to our of our product managing range to co-promoting directly commercial potential from commercial commercial shareholders candidates best consider we rights. structures first-in-category and believe and products every is And essentially in means can or for do fully Daré partnering we what or we case. the that

patients for and as opportunities in will as unlock the allows and that care are with which fortunate for product to us these allow prioritize for believe doing unique are portfolio specifically for are most a us because that be We shareholders. to currently of the to all such position we we structures, a providers, it well will interested And in way DARE-BVX. diversified to have health consider in we DARE-BVX, value payors

commercialization going the and providing following partnership And over additional insights a financial to that, update. the with top I'm turn on forward Lisa later to for announcement look to we the this year. call DARE-BVX line data strategy you with So

Lisa Walters-Hoffert

John. XX, joining to XXXX. you, you us Daré for Thank all September And of ended the now results financial for thanks like summarize today. I to would quarter

know Daré product business novel you assemble, As to health. portfolio and model women's advanced of candidates in is a monetize

of result, to and necessary portfolio development our clinical research through maintenance the including expenses and data other generate acquisition overhead, to advance milestones and consist candidates a and activities As corporate approval. our regulatory costs,

XX, September research quarter expenses XXXX the or million. were just were approximately expenses Administrative $XX,XXX expenses and development R&D approximately and $X.X license Daré approximately and General ended For million, $X.X were

In this for addition costs reflect Ovaprene DARE-LARCX Gates the program our on-going DARE-BVX grants and personnel Phase team, and Bill Foundation. preclinical related activities activities to R&D from DARE-LARCX the with by of of the primarily development costs R&D supported quarters to expenses X the study our Melinda

sales $XX.X loss comprehensive million. million. Such facility September warrants ATM quarter from the under $X.X line, with approximately at-the-market ended proceeds. and million XXXX the was and the or quarter of approximately months cash were and primarily Our generated in the our provided equivalents. for cash $X.X stock activities by proceeds equity Net approximately financing of was ended loan for nine XX cash exercise We

there cash and several given worth current their developments on the burn our over operating expenses. Now impact anticipated past highlighting few months, were and

award further Daré in of support under study the provide of support X.X an In are receipt DARE-LARCX to recognized for $XXX,XXX of also we we the in agreement that in that She Australia, earlier, we to their a total specifically million tax rejection Development grant a DARE-FRTX or the efficient. in team submitted. in as in eligible in application the with of funding proceeds total development grant under Child commenced time Australia's payment an of additional of innovative on based a year. Avomeen, pre-existing services with from the of a August, and As grants X and September, XXX,XXX foundation cash Foundation approximately of the receive to to incentive Health funding the in that support and very brings Gates Sabrina to September, this costs for remained million credit National R&D a Phase clinical allows Bill advancement pipeline Phase support Human which discussed development product maybe for a upto maximum available DARE-FRTX. receipt DARE-LARCX in X grant that study of DARE-HRTX associated Kennedy the funding activities, the program. Institute announced our we announced Also the will up from Recall program apply is in to study X million. the program. $XX.X under contract the manner and -- announced eligible R&D Avomeen with a Shriver Phase the with Melinda receive statements the of the both following Eunice to program form a noted and Currently, an notice development of X we specifically award the to eligible cost allowable of laboratory intend of financial our offset of assembled July, team to and XX.X% expenses then refundable In of cash companies assembled

to based summary, DARE-LARCX Gates the previous resources calls program us health for R&D will reduce Australian activities, collectively on incentive discussed Bill we our our Melinda as the in manage believe for well NIH development earnings the and or which to in Avomeen serve months of So partnerships during tax we DARE-FRTX, with as efficiently. grant and and Foundation grant help cost decisions, our our ahead these

X our through common million by November XX, strengthen of our cash we Now stock us, of subsequent for fees to position sales steps raising the under $X.X to the ATM equity it's net October period took line. end, from and further quarters or our approximately

were XX outstanding as Following of common these approximately million. activities XX, November and our shares stock yesterday, of

access grants, Since through we license of our our equity needs. to to working to cash to capital and continue raised warrant transactions, product M&A ways sale securities, have and advance non-dilutive candidates the our explore our exercises, inception, fees. option satisfy will additional We capital and

our to opportunistic not the we and value we maintain in to to need advance will such as only build and use endeavour candidates, highly be efficient to and but seeking capital of capital. that be creative We

their filed time. encourage and XX-Q our at discussion of touched capital COVID-XX, and to we investors its on And impact In financials terms affect review company adversely this to to call March our in over We factors on, and associated the the also our implant to our for results restrictions Sabrina are statements I notes uncertainties monitor financial continuing additional of like and operation, would and turn resources including financial our filed review Chris, the XX-K on-going potential was our clinical ability risk business, risk liquidity the our condition, governmental and to included we as to now more our in financial accuracy potential XXXX. and audited their that condition, business we surrounding when on any the pandemic, operator including many that responses, the to our are pandemic, to trials, the and impact the and capital XX raise factors Due detailed predict financial to needed. reasonable today. full with related Q&A. of unable on

Operator

Thank you. Capital [Indiscernible] line from with our And Dora comes a Roth [Operator question of first Partners. Instructions]

Your line is now open.

Unidentified Analyst

[Indiscernible] is Roth. This guys. Hi from

Just the update. and questions a again for of had thanks here couple

to know, how year, has end before about do DARE-BVX with looking really The to probably what the you're Daré the of thinking encouraging want that a what for. just is kind the think of supportive of on first everyone partnership, is I expected and is here. one you're just focused if filing, for

provide some going details you on that. I to some, was John said, think

partner? So take part partnered? you you Could what to definitely plan for are alone, looking this or this a have in you

Sabrina Martucci Johnson

speaking, comments John kind how point Yes, and take to we're really you. to that of addressing for out and course, some to, is the made to reinforce I'll maybe opportunity that this question of of Sabrina this

about touched of very that is diversified one things portfolio. as on we portfolio, the it's So Daré our a in diverse, both

number We have candidates in various stages of phases and a of development.

does allow to us that transaction of structures, different consider types And so a really number of right.

which partnering for definitely has did transaction product one One, we contraceptive are with to take of of there there's that a Ovaprene, a to right have they billion the a on you can few can right ways a aspects they type Daré different demonstrated transaction for like the consider to products Daré and portfolio structures that you variety variety that it. that to a that With was accretive build lot opportunity, of we And dollar can be can shareholders. continue range for reasons. include product structures And of commercialization. take with hand, with structures we can out variety product those commercial DARE-BVX felt flexibilities a a to approaches. that infrastructures, the take. So approaches licensing to for have fully managing co-promotion partner the over that's we like from other of for a there's contemplate and of we a with shareholders And brand actually lot to of thing of like all really specifically, can DARE-BVX, our that

who any to not that Ovaprene, someone portfolio. important build a potential to so is whether or bacterial a therapeutic it that really category. health is women's women's in which looking for we're actually category. Daré a unlike great the category, a a the It’s commercial addition intended is also, and a product, has health Ovaprene opportunity first to category think be can partnership for new vaginosis brand anyone So line great But in in we not. so like have to unique infrastructure build the be is obviously they

is BVX we value. of select So are possibilities of partners structured of hopefully we're objectives and around that how full looking shareholder a that number lot we are a range strategic a heard to as I'm in the of in structure think potential to we because going best with structures to John's And and and we Daré is and comments, that. are end, at talking what you reinforcing pertains select, we from it we the today. what that the have fits flexibility And beauty

John Fair

I Yes, would and exactly the what just echo that's you're when question. I actually, asked down wrote

best So optionality, sure our partnership opportunity, fit and shareholders for really finding the fit and then that making maximizing maintaining creating value it's opportunity, really structure. best we're really that about

be So, we make know we until hard but determined. anything back announce, on happen. that's to we're something that never that announced to end to working have Obviously, the

Unidentified Analyst

And Thank I into could just synergies deal? is in was that very And denovo structuring wondering I there's think thing, of another there. throw progressing Because terms that then that's it well. you some you. the possible into of deal,

Sabrina Martucci Johnson

Yes.

that this thank is a has take give to And you provide the we women's me you, health category that first these have a that variety having That opportunity, risk advance portfolio a our at health kind recognizing to does does deploy across I our to different development space. in in unique across us And mentioned, thing in front a give this investment And and to frankly, ways, mean, the as partnership and products. of I on in this of portfolio is uniquely I also creative To the of can the comments, to we're of want creative very have category. uniqueness variety programs my be creative opportunities that the look other of it allows that of company an and portfolio continue a of diversified beauties environment. say of things therapeutic that. simultaneously, in to indications to noted, and do, players a knowledge, profiles, our us first it So in one Daré profiles the that always all, opportunities But only opportunity structures of and challenging timeline do for touched portfolio reinforce of opportunity I and opportunities. it the all of they're suited of women's even create indications. very that in and not resources only deploy to stages, fact ways, we as have nature

are as what we timing. And So exploring, it's also the structure going who's other party, always, most what makes always sometimes but to make sense, noted, the is about it’s sense. John partnerships,

of types of partnership we as and programs decision DARE-BVX X instance, front you puts other potential we're, at. because those readout line specifically will program. So purposely up variables we all us to that And the explore top Phase that as in weighing opportunities, after noted, a partner I as fully. for different for for made look mentioned strongest those we provide But

Unidentified Analyst

Thanks, to data. guys looking the forward

Sabrina Martucci Johnson

Yes, worry. don’t

Operator

Dawson Instructions] from of a comes question Jason [Operator you. Kolbert with Thank line Our James. next

Your is open. now line

Jason Kolbert

balance partnering. Hi, the capital I keeping on see positive your when that of Preservation as options fronts. guys, open comes it to congratulations of on a and lot sheet,

and In terms re would the for us of of, be BVX, perceived great others, with therapy I can data. Thanks. that think primary endpoint helpful as be we assumptions just and it remind trial you if of and the probabilities would could hitting powering just familiarize that maybe what me of so ourselves the for

Sabrina Martucci Johnson

that opportunity that. you that highlight to for Thank and question,

So let's care start with the current standard today. of

So the the curates care current to in mid-XXs. standard has the of mid-XXs

includes for outcomes. with approved The compliance treatments is well challenging, and bacterial days, market of FDA and that on vaginosis, So vaginosis bacterial of challenge your all that every that's several many often is products in oral then treatments the vaginosis. as terms as which require the both administration

the challenges many those have of top products curates, the of you administered. and how on just So are those

but tend metronidazole however, antibiotics to rely predominantly the of And upon same or two so, clindamycin. they

we challenge, range are form. previously cure that X% vaginosis, a in dosage about. It's talked a rate that of using studied patients been delivering given and something because the in case experiencing, a has clindamycin. And vaginal has recurrent she's that a bacterial the to it's I benefits in BVX, highly vaginally, also So there's antibiotic administration this prefer of physicians symptoms that of and in a condition. indication The typically types

recurrent as oral product the as of avoid is be. where challenge much to administration want to with needs So vaginal antibiotics. you keeping just it administration possible frankly The

that tend need like that time need present, of what rates to really the cord, fight are they to cure antibiotics out be impacted vaginally, likely the clindamycin, products leak that you infection. to is resident has and the So negatively have to

and the that gel and it's formulation, to done hydro delivery one hydro delivery. gel platform, more heated and So is thermo temperature, viscous becomes drug in it's it's her adhesive bio innovation and once it thermosetting DARE-BVX body settings, that the quite so

product. So just it's administration one the of

So she do to it only once. has

the In trial the rate terms cure turn of nominate design. [ph] in to

cure, been thing at where looking studies of is they bacterial as products vaginosis, So terms have looking time, of finalize the we've part recent same sort signs in symptoms And the XXXX, at in bacterial calculation. some guidance. in clinical the or four. two distinguish of vaginosis, of But the condition kind and it's that been FDA always about that three permutation, years, across the much and they're developed nice become essentially, actually the in or clinical pretty their

that that So is vaginal very present, resolution looking specific a that specifically a [Indiscernible] present vaginosis, with and down then in vaginal XX% whether a a bacterial is below type called of reduction in typically, distinctive cells of there's you're now with sort you're this discharge response. of cell very looking and a looking odor at for associated percent inflammatory are you're reduction, sort distinctive to

how like products said So is kind for at you that array have across is of same pH been that I looked of as that and sometimes been cure. approved at symptoms And well that determine of looked the time bacterial that vaginosis. has

exceptions products range is program, right now of a our dose clean of are them attractive this of multiple initiated is are product. Phase and with oral most vaginal there potential It's to range that The by this are way, the a to because also, investigator treatments data benefits time encaptured dose there And So that a and administration. features mid-XXs, one and high of the but X were a is in very is few that some one all perception the administration's given her mid-XXs user. great how onetime around with it rate, that using points the XX. in that cure XX. going that same show second, the because formulation. maintained it end the to It's or to is XX of XX the time cure a in even are time about aesthetically XX% rate there multiple range, to is study today, most I'm but criteria, it bio-adhesive and of that that X approved in is, talk acceptability pilot Frankly, administration's.

of love what range, that formulation this do that that you an improvement we'd definitely is in onetime see so, need, we vaginal like, And we'd the clear curate see we over is don't a to mid-XXs. mid-XXs the And shows anything love range. very it, But to today know, that standard attractive. given your to need question gel of

what and you design trial expect. the of should terms In

there queue were a we over expected. that of ended total little patients study, the bit So we announced a than in the just XXX that higher up enrolling in we

in And thing we studies. fast any of study. we a because up fact, to one impact what on impact do our need not ended you see in of say so this and I'll enrollment that, you're COVID on support was We going lot that. is COVID And about did to enrollment over know target how enrollment hearing and

It's expected, higher so placebo. assessment test fine. The clue ended cure little to one, state had BV that to XX. ask is which primary that what up day of about, is And XX, to and it than discharge a we returning odor, we that I non two vaginal cells talked to endpoint at

I two HRTX of run COVID, So would were us. I'll least a, was portfolio both our pick highlight the XX studies. out to say day choices for if during programs clinical programs, that They're of to And this our going BVX. at clinical our obvious programs, also you're

longer, allowed using in studies valuable a get So which which frankly, than we now month. for we're commitment. us terms as information and they the they're quick lot that Ovaprene for are which really fairly of are to Cream planning And of duration of longer patient, are are a Sildenafil

terms what So endpoint, for should when in line, between the test that which primary we top announced of placebo. is arm it's separation cure two. statistical when around versus really in we looking the you active expect, we're And of

Jason Kolbert

and great me. thank Good course, for reminder really, was you a Of that really was helpful that luck. Thanks.

Sabrina Martucci Johnson

excited obviously, it. we're are we Yes, much. so about really you Thank

first the you company. a have exciting super is X always, Phase when As

Operator

session. concludes any call I this closing question-and-answer remarks. Sabrina turn Johnson will Martucci the now to today's for back And

Sabrina Martucci Johnson

Yes, little you, went we longer than thank a anticipated.

attending you have all you call. and than thank Q&A to start earlier taking the your thank patience, appreciate the We this So a But with afternoon. for we really sorry hoped. time conference you to little the

I take want So couple do minutes. to a

just a about. minutes leave talked Sorry, what leave summarize to one couple we

X top XXXX as we're really looking in Phase events data to wrapping XXXX. we're readout and the milestone So that with we to get for those. I that forward move for line up forward on planned And DARE-BVX, mentioned, to looking

in our I And specifically, and we're the I reminder into for want late like with of expecting key call remainder mid year. then just for terms close those a of said, stage So what to XXXX. this milestones programs the going of

data that discussing, would series this that DARE-BVX, been got of the NDA positive of from the Phase our as as a support submission a to the activities we've first that support top for is of half strategic X commercialization lead study assuming the readout we've line XXXX, before partnership regulatory to as been which the target. we've data in outcome, end year, talking And this United So to in States. about, well,

program, for of to as plan mentioned, I the we study intend start arousal that first quarter Phase so that So XXXX. our to in Xb disorder

top for support a year activities by readout start that we're And working line on, I we also Xb. XXXX for Phase the to a support readout then should would that expect allow by Ovaprene end something the We as of to are data data end continue pivotal believe line end XXXX study that by the of top XXXX. mentioned and certainly

of addition regulatory opportunities entire I John be As X categories that partnering as to discussing, that NIH for briefly, and under the data touched on XXXX announcements lookout the in in the the Phase discussing DAREFRTX X potential readout as Phase expect DARE-HRTX And I Q&A, on the as in and in to been noted, DARE-VBAX across first as and related grant, mentioned, both in will the XXXX remind program half pipeline been mentioned. population. on-going on cancer top be for course to well and as we activities portfolio first activities about milestones, breast our then but John health also to we our of focus and of the we've across geographies, as making women's we've as clinical want to monetize line continue products the in

mission. And progress. our our on importantly but updated forward certainly, and look for you our obviously, to dedication to grateful, keeping we're their we team, commitment to to So our shareholders,

you taking the thank today. for So time

Operator

this Thank call. you. today's gentlemen; for concludes ladies you and conference participating. Well Thank

now disconnect. may You

Daré Bioscience (DARE) 12 Nov 202020 Q3 Earnings call transcript